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Abstract
Flaviviruses are a group of human pathogenic, enveloped RNA viruses that includes dengue (DENV), yellow fever (YFV), West
Nile (WNV), and Japanese encephalitis (JEV) viruses. Cross-reactive antibodies against Flavivirus have been described, but
most of them are generally weakly neutralizing. In this study, a novel monoclonal antibody, designated mAb 2A10G6, was
determined to have broad cross-reactivity with DENV 1–4, YFV, WNV, JEV, and TBEV. Phage-display biopanning and
structure modeling mapped 2A10G6 to a new epitope within the highly conserved flavivirus fusion loop peptide, the
98DRXW
101 motif. Moreover, in vitro and in vivo experiments demonstrated that 2A10G6 potently neutralizes DENV 1–4, YFV,
and WNV and confers protection from lethal challenge with DENV 1–4 and WNV in murine model. Furthermore, functional
studies revealed that 2A10G6 blocks infection at a step after viral attachment. These results define a novel broadly flavivirus
cross-reactive mAb with highly neutralizing activity that can be further developed as a therapeutic agent against severe
flavivirus infections in humans.
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Introduction
Arthropod-borne flaviviruses, including dengue (DENV), Japa-
nese encephalitis (JEV), West Nile (WNV), yellow fever (YFV) and
tick-borne encephalitis viruses (TBEV), are related important
human pathogens that cause severe hemorrhagic and encephalitic
diseases of global impact [1,2]. The mature flavivirus virion is
spherical and enveloped, with a single-stranded, positive-sense
RNA genome. Although the characteristics of these viruses are
well-defined, no specific antiviral drugs are currently approved for
clinical use against flavivirus infections. In viral diseases for which
a specific therapy is not yet available, antibody-based therapy
represents a promising alternative strategy. Neutralizing antibodies
have been shown to be effective in animal models, both as
prophylactics and as treatments for flavivirus infections [3–6]. Two
humanized monoclonal antibodies (hE16 and CR4373) against
WNV are in clinical trials [7].
Most neutralizing antibodies recognize the flaviviral envelope
protein (E), which is the major glycoprotein on the surface of
virions that plays a central role in receptor binding and membrane
fusion. X-ray crystal structures have revealed that the E protein of
flaviviruses has three domains, DI, DII and DIII [8–9]. Most
potent type-specific and subcomplex-reactive neutralizing mono-
clonal antibodies (mAbs) mainly recognize the epitopes on DIII
[10–14], which has been implicated in receptor binding. DII is
formed from two extended loops that project from DI and contains
a highly conserved fusion loop at its tip, i.e., amino acid residues
98–110, that interacts with the membranes of the target cell during
fusion. Flavivirus cross-reactive mAbs have been reported, most of
them directed against DII, with variable and less neutralizing
profiles [15–18]. To date, only a few neutralizing mAbs against
flaviviruses have been mapped to the fusion loop. Consequently,
the precise antigenic structures of fusion loops and their functions
in the protective immune response and pathogenesis remain
poorly understood.
In this study, a novel flavivirus cross-reactive mAb, 2A10G6,
directed against the highly conserved fusion loop, was generated
and characterized. In vitro and in vivo neutralizing profiles of mAb
2A10G6 suggest that it is an ideal candidate for treating severe
flavivirus infections.
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Ethics Statements
All animal experimental procedures were carried out in strict
accordance with the guidelines of the Animal Experiment
Committee of the State Key Laboratory of Pathogen and
Biosecurity, Ministry of Science and Technology of the People’s
Republic of China, and were approved by the Animal Experiment
Committee of the State Key Laboratory of Pathogen and
Biosecurity.
Cells and viruses
BHK21 cells were maintained in Dulbecco’s Modified Essential
Medium supplemented with 10% fetal bovine serum (FBS)
(ExCell). Mosquito C6/36, mouse myeloma SP2/0 and hybrid-
oma cells were maintained in RPMI 1640 medium supplemented
with 10–20% FBS. All cells were maintained in a 5% CO2
incubator at 37uC, except for the C6/36 cells, which were
maintained at 28uC.
The flavivirus strains used in this study were DENV1-128,
DENV2-43, DENV3-80-2, DENV4-B5, YFV-17D, WNV-chin01,
JEV-BJ-01, and TBEV-Senzhang. Viruses were prepared from
culture supernatants of infected mosquito C6/36 cells or infected
suckling mouse brain suspensions.
mAb preparations
Six-week-old female BALB/c mice were subcutaneously
immunized twice at 3-week intervals with 400 ml of heat-
inactivated DENV2 emulsified in Freund’s complete or incom-
plete adjuvant (Sigma). Three days after a final immunization with
virus antigens (infected sulking mouse brain suspensions) alone,
spleen cells from the mice and mouse myeloma SP2/0 cells were
fused and maintained according to the standard procedure [19].
Hybridomas were screened for secretion of anti-DENV2 specific
mAbs using an indirect immunofluorescence assay, and then E-
specific mAbs were identified by immunostaining of BHK21 cells
transfected with plasmids expressing the prM-E protein. The
hybridoma producing mAb 2A10G6 (IgG1) was cloned twice via
limiting dilutions of the cells. mAb 2A10G6 was purified from
mouse ascites using protein A affinity columns (GE).
Indirect immunofluorescence assay
Indirect immunofluorescence assays (IFA) were performed as
follows. Briefly, BHK21 cells were infected with various flavivirus
strains and fixed with ice-cold acetone. Cells were incubated with a
100-fold dilution of mAb 2A10G6 or normal mouse serum. After
60 min of incubation at 37uC, cells were washed three times with
phosphate-buffered saline (PBS). Cells were then treated with a
200-fold dilution of FITC-conjugated anti–mouse IgG (KPL) in
0.02% (w/v) Evans blue for 30 min at 37uC and rinsed with PBS.
After five washes in PBS, positive cells were detected using a
fluorescent microscope.
Western blot analysis
The DENV2 prME proteins were expressed in eukaryotic
systems following the manufacturer’s instructions and as previously
described [20,21]. Briefly, pcDNA3.1-based plasmids encoding the
DENV2 prME genes were constructed. Then, BHK21 cells were
transiently transfected with recombinant plasmids encoding the
prME protein or with empty pcDNA3.1 (control) using Lipofecta-
mine 2000 reagent (Invitrogen).
At 48 h after transfection, cultured cells were lysed and
analyzed by western blotting. Briefly, cell lysates containing the
prME protein were separated using 12% SDS-PAGE and
transferred to nitrocellulose membranes. The membranes were
blocked with PBST containing 5% skim milk and then reacted
with the appropriate mAb 2A10G6 at room temperature (RT) for
1 h. Subsequently, membranes were washed three times with
0.1% Tween 20/Tris-buffered saline (TBST) and incubated with
alkaline phosphatase–conjugated goat anti-mouse secondary
antibody (1:1,000). Following incubation for 1 h at RT, the
membranes were washed three times with TBST and developed
with NBT/BCIP (KPL).
Indirect enzyme-linked immunosorbent assay
The DENV2 DI–DII or DIII was expressed in Escherichia coli as
a fusion protein with thioredoxin following the manufacturer’s
instructions and as previously described [22]. Briefly, the pET32a-
based plasmid (Novagen) encoding DI–DII, residues 1 to 297, or
DIII, residues 298 to 400, of the DENV2-43 strain was
constructed. Then the recombinant DI–DII or DIII fusion protein
was expressed in the E. coli strain BL21 (DE3) after induction with
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG). The crude
cell debris was denatured using 8 M urea, refolded by step dialysis
and purified over a nickel-chelated column (Pierce).
An indirect ELISA was used to investigate the specificity of mAb
2A10G6 for the viral antigen. Briefly, 96-well microtiter plates
were coated overnight at 4uC with recombinant DI–DII or DIII
protein (1 mg/ml) in a pH 9.6 carbonate buffer. Plates were
washed three times with PBST and blocked for 2 h at 37uC with
PBST containing 5% skim milk. Subsequently, plates were rinsed
five times in PBST and then incubated with different concentra-
tions of 2A10G6 in triplicate for 1 h at RT. Plates were washed
five times and then incubated with peroxidase-conjugated goat
anti–mouse IgG (1:5000) (KPL) for 1 h at RT. Plates were washed
five times and then sequentially incubated with TMB substrate
(Promega). The reaction was stopped by the addition of 2 N
H2SO4 to the medium, and emission (450 nm) was read using a
microplate reader (Beckman).
Phage-display biopanning assay
Phage-display experiments were performed as previously de-
scribed [23,24]. Briefly, 100 mg/ml anti-DENV antibody 2A10G6
was immobilized on 96-well plate. Phages [1.5610
11 plaque-
forming units (PFU)] from the Ph.D.-12 Phage Display Peptide
Library (New England Biolabs) were incubated at 37uC for 1 h with
immobilized 2A10G6. The wells were washed five times with
TBST. Then, the phages that bound 2A10G6 were amplified by
direct infection of E. coli ER2738. The amplified phages were
purified by precipitation with 20% PEG 8000/2.5 M NaCl and
used in the next cycle. Three rounds of selection were routinely
performed. The immunopositive phage clones were screened by
ELISA and further characterized by DNA sequencing.
Sequence alignment and molecular modeling
Nucleotide and deduced amino acid sequences encoding the E
genes of the flaviviruses tested were obtained from GenBank. The
NCBI accession numbers are FJ176780 (DENV1-128), AF204178
(DENV2-43), AF317645 (DENV3-80-2), AF289029 (DENV4-B5),
X03700 (YFV-17D), AY490240 (WNV-chin01), L48961 (JEV-
BJ01) and AY174188 (TBEV-Senzhang). Sequence analysis was
performed using MEGALIGN in the Lasergene software (DNAs-
tar).
Based on the crystal structures of DENV-2 E protein (PDB
code: 1OK8), the probable epitope of 2A10G6 was analyzed using
Discovery studio 2.0 (Accelrys). The location and structure of the
2A10G6 epitope in the three known E protein crystal structures of
Flavivirus Cross-Neutralizing mAb
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also analyzed.
Neutralization assay
Five-fold serial dilutions of 2A10G6 were added to approxi-
mately 200 PFU of a variety of flavivirus strains and incubated at
37uC for 60 min. Then, the mixture was added to BHK21 cell
monolayers in a 6-well plate in duplicate and incubated for 60 min
at 37uC. The supernatant was removed, and 3 ml of 1.0% (w/v)
LMP agarose (Promega) in DMEM plus 4% (v/v) FBS was layered
onto the infected cells. After further incubation at 37uC for 4 to 7
days, the wells were stained with 1% (w/v) crystal violet dissolved
in 4% (v/v) formaldehyde to visualize the plaques. The percentage
of plaque reduction was calculated as previously described [13].
Animal experiments
DENV 1–4 were prepared from infected suckling mice brain
suspensions. Viruses (10
4 PFU/ml) were mixed with an equal
volume of serial dilutions of 2A10G6 and incubated for 60 min at
37uC. Then the mAb-virus mixture was injected intracerebrally
into 1-day-old suckling mice. The control group only received PBS
diluent. The animals were monitored daily for clinical signs of
infection, including ruffled hair, a hunched back, paralysis, and
death, for 3 weeks. For antibody protection against West Nile virus
challenge, groups of 4-week-old female Balb/C mice were treated
by intraperitoneal injection with 200 mg of 2A10G6 or PBS one
day before or after challenge with 40 PFU of WNV, respectively.
Mice were then monitored daily for 15 days for mortality.
Protection significance was evaluated using the log-rank test and
compared to the PBS controls.
Cell-binding assay
Individual mAbs (50 mg/ml of 2H11, 2A10G6, or 2B8) or BSA
was incubated with 10
3 PFU of DENV2 for 60 min at 4uC. The
virus–mAb mixtures were then added to BHK21 cells in 12-well
plates for 60 min on ice. Unbound virus was removed after three
washes with prechilled PBS. Total RNA was extracted from
infected cells using Trizol reagent (Invitrogen), and viral RNA was
quantified by real-time RT-PCR as previously described [25].
Pre- and post-adsorption inhibition assay
Neutralization of DENV2 before or after adsorption to BHK21
cells was performed using 10
2 PFU of DENV2 and serial dilutions
of 2A10G6 or 2B8 essentially as described previously [26]. In the
post-adsorption assay, DENV2 firstly were added to BHK21 cells
for 60 min at 4uC, then the mAb was added and incubated for
additional 60 min at 4uC. In the pre-adsorption assay, the mAb
was firstly incubated with BHK21 cells for 60 min at 4uC before
DENV was added. After three times washes with PBS, the PRNT
protocol was followed as described above.
Results
Characterization of the flavivirus cross-reactive mAb
MAb 2A10G6 was originally identified as a DENV2-specific
mAb by indirect immunofluorescence assay (Fig. 1A). To first
determine whether the viral surface glycoprotein is recognized by
2A10G6, the reactivity of 2A10G6 to prME protein was examined
by western blotting. As expected, 2A10G6 reacted with BHK21
cells transfected with the recombinant plasmid expressing the
DENV2 prME protein, suggesting that 2A10G6 is directed against
the DENV2 prME protein (Fig. 1B). Further, to determine the
domain of the DENV2 E protein responsible for binding, an
indirect ELISA was used to detect the specific binding of 2A10G6
with the recombinant DI–DII or DIII of the DENV2 E protein.
We found that 2A10G6 only reacted with DI–II of the DENV E
protein (Fig. 1C). Subsequently, the cross-reactivity of 2A10G6
was tested by IFA using other DENV serotypes and related
flaviviruses. We detected cross-reaction of 2A10G6 with DENV 1–
4, YFV, WNV, JEV, and TBEV (Fig. 1A). Therefore, a broadly
flavivirus cross-reactive mAb 2A10G6 was identified.
The specific site recognized by 2A10G6 is the
98DRXW
101
motif, located at the tip of the fusion loop of E protein
To map the epitope determinants of 2A10G6, a standard phage-
display technique was performed. After three rounds of panning, 94
positive phage clones were identified and subjected to DNA sequence
analysis. The results showed that 86 of the positive clones displayed
12 amino acid residues in common, i.e., SNFFDRTWPKLT; the
other three clones displayed YNFFDRTWPKLT, SHRQHET-
DRNWP, or NYPEDFFQRTWP. Specifically, seven residues,
FFDRTWP, were conserved in these immune-positive phage clones,
and the other five residues were random. Thus, the binding sites of
2A10G6 were deduced to be FFDRTWP.
We next compared this peptide with the amino acid sequences
of E proteins of DENV1–4, YFV, WNV, JEV, and TBEV and
found that all these flavivirus strains shared the same amino acids
at positions 98 (D), 99 (R), and 101 (W) within the highly
conserved N-terminal fusion loop peptide of the E protein DII
(Fig. 2). To verify that the
98DRXW
101 motif was recognized by
2A10G6, a peptide (MVDRGWG) corresponding to the amino
acids of the DENV2 E protein was synthesized, and the reactivity
of 2A10G6 to the synthetic peptide was determined by ELISA.
The results showed that 2A10G6 specifically reacted with the
synthetic peptide MVDRGWG (data not shown), suggesting that
this region containing the three common residues constitutes a
mimotope of the 2A10G6 epitope.
Furthermore, three-dimensional structural analysis showed that
the
98DRXW
101 motif was located at the tip of the fusion loop of
the DENV2 E protein (Fig. 3A). The structure of the 2A10G6
epitope in the three known E protein structures was compared
(Fig. 3B). The comparison indicated that the conformational
epitope formed by the three residues D, R, and W was similar
among flaviviruses (Fig. 3B). Together, these findings suggest that
2A10G6 recognizes a new epitope within the flavivirus fusion loop.
Neutralizing and protective profiles of 2A10G6
To investigate the neutralizing and protective potential of mAb
2A10G6, the neutralizing activities of 2A10G6 for various flavivirus
strains were assessed using a standard plaque reduction neutraliza-
tion assay. 2A10G6 exhibited high neutralizing activity against
DENV 1–4 and YFV, with 50% plaque reduction neutralization
titers (PRNT50) of 2, 1.5, 2.1, 1.8, and 3.6 mg/ml, respectively.
WNV was also neutralized by 2A10G6 at a PRNT50 of 46 mg/ml.
Although IFA results (Fig. 1) showed that 2A10G6 can also
recognize JEV and TBEV, no neutralizing activity of 2A10G6 was
observed for JEV and TBEV (Fig. 4). These results indicate that
2A10G6 can potently neutralize DENV 1–4, YFV, and WNV.
To characterize the protection profile of 2A10G6 in vivo,a n
established suckling model was employed to analyze the protective
efficacy of 2A10G6 against lethal DENV 1–4 infection. The
control mice developed typical neurological symptoms and died at
6 to 7 days post-infection. As shown in Fig. 5, 2A10G6 treatment
showed protection against DENV 1–4 in a dose-dependent
manner. Especially, treatment of 100 mg/ml 2A10G6 conferred
full protection against lethal DENV2 challenge, and 20 mg/ml and
4 mg/ml 2A10G6 protected 89% and 40% of infected mice from
lethal challenge, respectively (Fig. 5B). For infection with
Flavivirus Cross-Neutralizing mAb
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protection, and 53%, 77%, and 73% of the infected mice survived
after challenge, respectively. Statistical analysis using the log-rank
test showed that survival rate of 2A10G6-treated mice were
significantly higher than that of PBS controls, indicating that
2A10G6 confers protection against DENV 1–4 infection in vivo.
Additionally, the protection profile of 2A10G6 against WNV was
also investigated in mice. The results (Fig. 6) showed that
prophylactic administration with a single dose of 200 mgo f
2A10G6 conferred 80% protection in mice. Most importantly, 3
of8 (37.5%) micesurvivedwhen 2A10G6 was administeredone day
after WNV challenge. Log rank analysis showed that a significant
difference among groups between 2A10G6 and PBS control. There
results strongly indicated the therapeutic potential of 2A10G6 in
antibody based therapy against severe flavivirus infections.
Mechanism of 2A10G6-mediated neutralization
To further define the mechanism of 2A10G6-mediated
neutralization of dengue virus, binding inhibition assays were
Figure 1. Characterization of mAb 2A10G6 in vitro.A .Cross-reactivity of 2A10G6 with four DENV serotypes and four other representative
flaviviruses determined by indirect immunofluorescence analysis. BHK21 cells were infected separately with DENV1–4, YFV, WNV, JEV, or TBEV. Three
to 5 days after infection, cells were fixed and analyzed by IFA with 2A10G6. Uninfected cells were run simultaneously as negative controls. B. The
specificity of 2A10G6 for the DENV2 prME protein. BHK21 cells were transiently transfected with the recombinant plasmid encoding the prME protein
or with a control vector, empty pcDNA3.1. At 48 h after transfection, cultured cells were lysed and analyzed by western blotting with 2A10G6. C. The
specificity of 2A10G6 for the DENV2 DI–DII peptide. The DENV2 DI–DII peptide was expressed in E. coli as a fusion protein with thioredoxin, and
binding of different concentrations of 2A10G6 with DENV2 antigen and recombinant DI–DII peptide was detected by ELISA.
doi:10.1371/journal.pone.0016059.g001
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or without (2H11) neutralizing activity were used as controls. As
expected, 2B8 significantly (P,0.01) inhibited virus binding by
3.1-fold, whereas BSA protein or 2H11 failed to inhibit virus
binding (Fig. 7A). Although 2A10G6 can bind to DENV E
protein (Fig. 1), 2A10G6 did not inhibit virus binding, suggesting
that the activity of 2A10G6 may not involve the blockade of cell
attachment.
Because 2A10G6 supposedly recognizes the fusion loop, it
might inhibit a step after cellular attachment. Therefore, we
performed a pre- and post-adsorption inhibition assay. 2A10G6 or
2B8 were incubated with DENV2 before or after its binding to a
monolayer of BHK21 cells, and virus titer was measured by a
plaque reduction assay. As expected, both 2A10G6 and 2B8
neutralized infection when applied before the binding of the virus.
However, 2A10G6, but not 2B8, inhibited DENV infection when
added after virus adsorption to the cell surface (Fig. 7B). These
results indicate that 2A10G6-mediated neutralization occurs
primarily after dengue virus cellular attachment.
Discussion
In the present study, we generated and characterized a novel
broadly flavivirus cross-reactive mAb, 2A10G6, that strongly
neutralized several flavivirus infections in vitro and protected mice
against lethal DENV1–4 and WNV infection in vivo. Furthermore,
2A10G6 recognized the highly conserved fusion loop peptide
98DRXW
101. Functional experiments suggested that 2A10G6
neutralized viral infectivity at a post-attachment step in the viral
life cycle.
During neutralization in vitro, 2A10G6 displayed potent
neutralizing activities against DENV1–4, YF, and WN viruses
but was unable to neutralize JE and TBE viruses. Several flavivirus
cross-reactive mAbs have been reported to have neutralizing
activities. For example, a humanized mAb, 1A5, derived from a
chimpanzee has similar cross-reactivities but different neutralizing
activities for DENV1–4 [27]. Another study showed that mAb
against the WNV E protein cross-reacted with DENV1–4 but only
neutralized DENV2 and DENV4 [28]. Our results indicate that
2A10G6 is a more broad-spectrum neutralizing mAb in
comparison with other reported mAbs. Consistent with neutral-
ization in vitro, 2A10G6 had potent protective efficacies against
DENV1–4 and WNV in vivo, although these efficacies were
somewhat different.
We mapped the epitope of 2A10G6 to the
98DRXW
101 motif in
the highly conserved N-terminal fusion loop at the tip of DII in the
E protein. Three-dimensional structural analyses based on the
crystal structures of DENV2 E protein revealed that the three
Figure 2. Comparison of the amino acid sequences of flavivirus E proteins. Amino acids at positions 72 to 120 are shown. Boxed residues
indicate that positions 98 (green), 99 (blue), and 101 (red) were highly conserved among the flaviviruses examined and constitute a conformational
epitope.
doi:10.1371/journal.pone.0016059.g002
Figure 3. Structural mapping of the 2A10G6 epitope. A. the structure of the 2A10G6 epitope in the crystal structure of DENV2 E protein.
Residue numbering is based on the E gene sequences. The regions in red are thought to be structurally near these three residues. B. Three-
dimensional comparisons of the 2A10G6 epitope in the three known crystal structures. DENV2, WNV, and TBEV E proteins are in shades of red, blue,
and cyan, respectively.
doi:10.1371/journal.pone.0016059.g003
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surface and constitute a novel conformational epitope. These three
amino acids are highly conserved among flaviviruses, including
DENV 1–4, WNV, JEV, YFV, and TBEV (Fig. 3). Previous
studies reported that several mAbs recognize a set of overlapping
epitopes that form an antigenic site on the fusion loop surface of
DII. For instance, mAb E53 recognizes an epitope including
residues within the fusion loop and the adjacent bc-loop in DII of
E protein [17,29]. Similarly, the epitope of Mab11 was mapped by
yeast surface display to include residues in the fusion loop (W101,
G104, and G106) [30]. Furthermore, W101, L107, and F108 were
also found to be shared by several different but overlapping
epitopes recognized by the predominantly cross-reactive anti-E
antibodies present in polyclonal sera from patients with dengue
primary infection [31,32]. In addition, our structural analysis
indicated that the binding sites of 2A10G6 might involve other
surface-exposed residues that are spatially close to these three
residues (the red region in Fig. 3A). Thus, the 2A10G6 epitopes
represent novel antigenic sites for a potently cross-neutralizing
antibody on the N-terminal fusion loop.
Among the known structures of flavivirus E protein, the
backbones of the fusion loop are highly similar. Nine residues in
Figure 4. Neutralization activity of 2A10G6 to various flavivirus
strains. Viruses were mixed with 2A10G6 at different concentrations.
Neutralization activities were evaluated by plaque reduction assays
using BHK21 cells.
doi:10.1371/journal.pone.0016059.g004
Figure 5. Protection of 2A10G6 against DENV 1-4 in suckling mice. 2A10G6 at 100, 20, or 4 mg/ml was incubated with 10
4 PFU/ml of DENV 1–
4 and inoculated into brains of suckling mice. Mortality was the outcome measured. Viruses with PBS were included as a negative control. The
number of animals for each antibody dose ranged from 9 to 12. Kaplan–Meier survival curves were analyzed by the log-rank test and compared to
curves of the PBS controls. Significant differences are indicated by asterisks (*** p,0.001, ** p,0.01 and * p,0.05). A, B, C, and D represent DENV1,
DENV2, DENV3, and DENV4 infection, respectively.
doi:10.1371/journal.pone.0016059.g005
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post-fusion structure [9,33]. Therefore, the 2A10G6 epitope might
determine membrane fusion and cross-neutralizing and may be a
good target for broad-spectrum therapeutic antibodies or other
antiviral therapeutics. However, like many fusion loop–specific
neutralizing mAbs, 2A10G6 showed different neutralizing activ-
ities against different strains, suggesting the existence of subtle
structural differences in this region around the 2A10G6 epitope
that perhaps involve the polarities and side chain orientations of
structurally neighboring but less-conserved amino acids. In
addition, the exposed epitopes available for antibody recognition
in the structural transition process are likely to vary in different
flaviviruses [12,34], giving mAb 2A10G6 similar but distinct cross-
neutralizing reactivity profiles.
Our experiments also showed that 2A10G6 did not significantly
inhibit cellular attachment of DENV2 to BHK21 cells, but that it
inhibited infection when added after virus binding, suggesting that
2A10G6 neutralizes viral infectivity at a post-attachment step in
the viral life cycle. Generally, antibodies have the potential to
neutralize the infectivity of flaviviruses by interfering with several
steps of the virus entry pathway, including attachment, internal-
ization and fusion, perhaps depending on the locations of their
binding sites [6,35]. Previous studies have shown that mAbs
against the TBEV fusion loop were effective at blocking liposomal
fusion [36]. However, E53 inhibited infection primarily by
blocking viral attachment to some cells [17] or by blocking the
transition from an immature to a mature structure [29].
Flavivirus infection can cause fever, encephalitis, hemorrhagic
disease, flaccid paralysis and death in humans. In the last decade,
the flaviviruses have re-emerged as aggressive human pathogens
causing an increased number of infections worldwide [2].
Although much effort has been made to develop effective antiviral
drugs, no specific therapies are currently available. DENV
infection represents a major public health problem with an
estimated 2.5 billion people at risk of infection in tropical and
subtropical countries, mainly southeast and south Asia, Central
and South America, and the Caribbean [37]. In additional,
multiple flavivirus infections have been reported in the same areas,
Figure 6. Protetcion of 2A10G6 against WNV in mice. Group of 4-week-old Balb/C mice were administrated with 200 mg of 2A10G6 one day
before (A) or after (B) challenge with 40 PFU of WNV. PBS was included as a negative control. Kaplan–Meier survival curves were analyzed by the log-
rank test and compared to curves of the PBS controls. Significant differences are indicated by asterisks (** p,0.01 and * p,0.05).
doi:10.1371/journal.pone.0016059.g006
Figure 7. Mechanism of 2A10G6-mediated neutralization. A. Dengue virus binding to BHK21 cells. The DIII-specific neutralizing mAb 2B8
blocked cellular attachment significantly more than the DI–DII–specific neutralizing mAb 2A10G6 or controls, including no antibody (BSA) and the
non-neutralizing mAb 2H11. Fold reductions are reported with standard deviations as the average of four independent experiments. B. Pre- and post-
adsorption inhibition assays. Pre-binding of DENV2 with 2A10G6 or 2B8 significantly protected against infection (solid lines) (Pre). In contrast, 2A10G6
but not 2B8 inhibited infection when added after virus binding (dotted lines) (Post). Infection percentages at the different antibody concentrations
are shown with standard deviations.
doi:10.1371/journal.pone.0016059.g007
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For example, JEV and DENV are both endemic in many Asian
countries, whereas YFV and WNV are reported in Africa and
South America [1]. To control the growing public health problem
of flavivirus infection, new antiviral therapeutic strategies that
provide potent and broadly cross-protective host immunity are
therefore a global public health priority [7]. At present, human
mAb–based ‘‘passive’’ immunotherapies for these viruses are at a
very early stage of development, including for WNV [38]. Previous
studies in mice have shown that passive transfer of either
monoclonal or polyclonal antibodies can be protective against
homologous or heterologous DENV challenge [27,39–40]. For
this reason, mAb 2A10G6 may further be humanized into a
therapeutic antibody to treat DENV and other severe flavivirus
infections.
In summary, we generated and characterized a broadly
flavivirus cross-reactive mAb, 2A10G6, with in vitro and in vivo
neutralizing activity, and demonstrated the potential therapeutic
potential of humanized 2A10G6 for multivalent treatment against
severe flavivirus infections.
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